Trial Outcomes & Findings for An Extension to Study MD7108240 (NCT NCT00733304)

Last Updated: 2017-12-05

Results Overview

Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Intra-ocular pressure was recorded from Baseline up to Follow-up.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

42 participants

Primary outcome timeframe

Baseline (Day 1) and approximately up to 6 months

Results posted on

2017-12-05

Participant Flow

This was an extension study to protocol MD7108240 (NCT00612456). It was a multi-center, double-masked, randomized, parallel-group dose-ranging study of repeat topical ocular doses of pazopanib from 25 June 2008 to 9 September 2009. The study was conducted in 14 centers in the United States, Italy, and Australia.

Randomized participants without progression of age-related macular degeneration (AMD) and/or requiring rescue therapy during the 28-day treatment period in study MD7108240 (NCT00612456) were included in this study. A total of 42 participants were randomized in the study.

Participant milestones

Participant milestones
Measure	5 mg/mL TID Eligible participants received 5 milligram/milliliter (mg/mL) Pazopanib eye drops three times daily for a treatment period of five months.	2 mg/mL TID Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months.	5 mg/mL QD Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months.
Overall Study STARTED	19	15	8
Overall Study COMPLETED	12	12	3
Overall Study NOT COMPLETED	7	3	5

Reasons for withdrawal

Reasons for withdrawal
Measure	5 mg/mL TID Eligible participants received 5 milligram/milliliter (mg/mL) Pazopanib eye drops three times daily for a treatment period of five months.	2 mg/mL TID Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months.	5 mg/mL QD Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months.
Overall Study Adverse Event	3	0	0
Overall Study Lack of Efficacy	0	0	2
Overall Study Lost to Follow-up	0	1	0
Overall Study Physician Decision	3	1	3
Overall Study Withdrawal by Subject	1	1	0

Baseline Characteristics

Safety Population

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months.	Total n=42 Participants Total of all reporting groups
Age, Customized 55 to 88 aged	19 Participants n=93 Participants	15 Participants n=4 Participants	8 Participants n=27 Participants	42 Participants n=483 Participants
Sex: Female, Male Female	15 Participants n=93 Participants • Safety Population	7 Participants n=4 Participants • Safety Population	5 Participants n=27 Participants • Safety Population	27 Participants n=483 Participants • Safety Population
Sex: Female, Male Male	4 Participants n=93 Participants • Safety Population	8 Participants n=4 Participants • Safety Population	3 Participants n=27 Participants • Safety Population	15 Participants n=483 Participants • Safety Population
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants • Safety Population	0 Participants n=4 Participants • Safety Population	0 Participants n=27 Participants • Safety Population	0 Participants n=483 Participants • Safety Population
Race (NIH/OMB) Asian	0 Participants n=93 Participants • Safety Population	0 Participants n=4 Participants • Safety Population	0 Participants n=27 Participants • Safety Population	0 Participants n=483 Participants • Safety Population
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants • Safety Population	0 Participants n=4 Participants • Safety Population	0 Participants n=27 Participants • Safety Population	0 Participants n=483 Participants • Safety Population
Race (NIH/OMB) Black or African American	0 Participants n=93 Participants • Safety Population	0 Participants n=4 Participants • Safety Population	0 Participants n=27 Participants • Safety Population	0 Participants n=483 Participants • Safety Population
Race (NIH/OMB) White	19 Participants n=93 Participants • Safety Population	15 Participants n=4 Participants • Safety Population	8 Participants n=27 Participants • Safety Population	42 Participants n=483 Participants • Safety Population
Race (NIH/OMB) More than one race	0 Participants n=93 Participants • Safety Population	0 Participants n=4 Participants • Safety Population	0 Participants n=27 Participants • Safety Population	0 Participants n=483 Participants • Safety Population
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants • Safety Population	0 Participants n=4 Participants • Safety Population	0 Participants n=27 Participants • Safety Population	0 Participants n=483 Participants • Safety Population

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population included all participants who received at least one dose of the study drug. Only those participants available at the time of assessment were analyzed.

Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. SBP and DBP were recorded from Baseline up to 6 months. At screening and Baseline, if the single measured value of blood pressure was above 150 millimeters of mercury (mm Hg) systolic or 95 mm Hg diastolic, then blood pressure measurement could not be repeated. If, the SBP was \<80 or \>140 mm Hg and DBP was \<40 or \>90 mm Hg, then measurement of BP was repeated. Three consecutive blood pressure readings that were less than 150 mmHg systolic and 95 mmHg diastolic were taken with each measurement separated by at least 1 hour.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period DBP, Month 1	3.5 Millimeters of mercury (mmHg) Standard Deviation 9.05	-0.4 Millimeters of mercury (mmHg) Standard Deviation 8.40	1.1 Millimeters of mercury (mmHg) Standard Deviation 3.98
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period DBP, Month 2	1.8 Millimeters of mercury (mmHg) Standard Deviation 8.79	1.6 Millimeters of mercury (mmHg) Standard Deviation 8.32	-0.5 Millimeters of mercury (mmHg) Standard Deviation 7.09
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period DBP, Month 3	3.9 Millimeters of mercury (mmHg) Standard Deviation 8.03	-0.9 Millimeters of mercury (mmHg) Standard Deviation 8.16	1.5 Millimeters of mercury (mmHg) Standard Deviation 7.42
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period DBP, Month 4	0.0 Millimeters of mercury (mmHg) Standard Deviation 8.49	-0.4 Millimeters of mercury (mmHg) Standard Deviation 6.09	0.0 Millimeters of mercury (mmHg) Standard Deviation 6.12
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period DBP, Month 5	8.6 Millimeters of mercury (mmHg) Standard Deviation 11.83	1.8 Millimeters of mercury (mmHg) Standard Deviation 7.40	4.7 Millimeters of mercury (mmHg) Standard Deviation 19.73
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period DBP, Follow-up	3.3 Millimeters of mercury (mmHg) Standard Deviation 9.04	1.8 Millimeters of mercury (mmHg) Standard Deviation 9.59	-2.8 Millimeters of mercury (mmHg) Standard Deviation 11.11
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period SBP, Month 1	-2.4 Millimeters of mercury (mmHg) Standard Deviation 10.55	0.5 Millimeters of mercury (mmHg) Standard Deviation 12.68	-2.3 Millimeters of mercury (mmHg) Standard Deviation 9.22
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period SBP, Month 2	-0.4 Millimeters of mercury (mmHg) Standard Deviation 14.91	-3.0 Millimeters of mercury (mmHg) Standard Deviation 15.37	-4.0 Millimeters of mercury (mmHg) Standard Deviation 7.91
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period SBP, Month 3	-0.5 Millimeters of mercury (mmHg) Standard Deviation 16.29	1.8 Millimeters of mercury (mmHg) Standard Deviation 12.46	0.8 Millimeters of mercury (mmHg) Standard Deviation 10.63
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period SBP, Month 4	-4.1 Millimeters of mercury (mmHg) Standard Deviation 10.37	-1.9 Millimeters of mercury (mmHg) Standard Deviation 6.98	-1.0 Millimeters of mercury (mmHg) Standard Deviation 8.83
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period SBP, Month 5	0.0 Millimeters of mercury (mmHg) Standard Deviation 17.16	-1.3 Millimeters of mercury (mmHg) Standard Deviation 14.71	-9.7 Millimeters of mercury (mmHg) Standard Deviation 1.15
Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period SBP, Follow-up	0.6 Millimeters of mercury (mmHg) Standard Deviation 12.65	0.9 Millimeters of mercury (mmHg) Standard Deviation 13.44	-2.3 Millimeters of mercury (mmHg) Standard Deviation 5.99

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only the participants available at the time of assessment were analyzed.

Heart rate was measured over 6 months. Baseline value was recorded on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value. Heart rate measurement were repeated in case it was in range \< 50 beats per minute (bpm) or \>110 bpm.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Heart Rate Over Period Month 1	-0.6 bpm Standard Deviation 9.81	2.4 bpm Standard Deviation 9.19	5.1 bpm Standard Deviation 9.82
Change From Baseline (Day 1) in Heart Rate Over Period Month 2	-0.3 bpm Standard Deviation 8.50	1.3 bpm Standard Deviation 8.89	5.0 bpm Standard Deviation 9.52
Change From Baseline (Day 1) in Heart Rate Over Period Month 3	1.4 bpm Standard Deviation 10.92	-2.5 bpm Standard Deviation 13.90	1.3 bpm Standard Deviation 7.37
Change From Baseline (Day 1) in Heart Rate Over Period Month 4	-2.0 bpm Standard Deviation 9.80	0.7 bpm Standard Deviation 9.85	-2.2 bpm Standard Deviation 8.90
Change From Baseline (Day 1) in Heart Rate Over Period Month 5	-0.8 bpm Standard Deviation 7.70	0.6 bpm Standard Deviation 10.90	9.3 bpm Standard Deviation 20.03
Change From Baseline (Day 1) in Heart Rate Over Period Follow-up	-0.2 bpm Standard Deviation 6.78	-1.8 bpm Standard Deviation 8.07	5.0 bpm Standard Deviation 11.22

PRIMARY outcome

Timeframe: Baseline (Day 1), Month 2, 5 and approximately up to Month 6

Population: Safety population. Only the participants available at the time of assessment were analyzed.

Albumin and hemoglobin values were recorded at Baseline, Month2, and till follow-up (Month 6). Baseline was recorded on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period Albumin, Month 2	0.6 Grams per liter Standard Deviation 1.46	-0.7 Grams per liter Standard Deviation 1.38	-1.1 Grams per liter Standard Deviation 1.96
Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period Albumin, Month 5	0.3 Grams per liter Standard Deviation 2.15	-1.0 Grams per liter Standard Deviation 1.34	-3.0 Grams per liter Standard Deviation 1.00
Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period Albumin, Follow-up	-0.4 Grams per liter Standard Deviation 1.67	-1.1 Grams per liter Standard Deviation 1.45	0.2 Grams per liter Standard Deviation 1.30
Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period Hemoglobin, Month 2	2.1 Grams per liter Standard Deviation 6.95	-0.5 Grams per liter Standard Deviation 4.22	-1.3 Grams per liter Standard Deviation 8.35
Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period Hemoglobin, Month 5	-0.2 Grams per liter Standard Deviation 10.04	0.3 Grams per liter Standard Deviation 5.05	-6.0 Grams per liter Standard Deviation 0.00
Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period Hemoglobin, Follow-up	-0.2 Grams per liter Standard Deviation 8.65	0.4 Grams per liter Standard Deviation 8.66	2.5 Grams per liter Standard Deviation 5.26

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only the participants available at the time of assessment were analyzed.

ALP, ALT and AST values were measured over 5 months and till the follow-up period. Baseline value was recorded pre-dose Day 1. Change from Baseline is the value at indicated time point minus the Baseline value.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only the participants available at the time of assessment were analyzed.

Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. The above mentioned hematological parameters were recorded from Baseline up to 5 months.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only the participants available at the time of assessment were analyzed.

Change from Baseline is the value at indicated time point minus the Baseline value. Over here, the change is % Basophils at month x - % Basophils at Baseline. Baseline measurement was recorded at Day 1. Percentage change in the hematological parameter mentioned above was recorded from Baseline up to 5 months.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only those participants available at the time of assessment were analyzed.

Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Direct bilirubin, total bilirubin, and creatinine were recorded from Baseline up to 6 months

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only those participants available at the time of assessment were analyzed.

Change from Baseline (Day 1) is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Calcium, chloride, carbon di oxide equivalent content (CO2), glucose, potassium, sodium, and urea/blood urea nitrogen (BUN) was recorded from Baseline up to Follow-up.

Outcome measures

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only those participants available at the time of assessment were analyzed

Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. MCV was recorded from Baseline up to Follow-up.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Mean Corpuscular Volume (MCV) Over Period Month 2	0.1 Femtoliters Standard Deviation 2.07	-0.2 Femtoliters Standard Deviation 1.20	-1.1 Femtoliters Standard Deviation 1.24
Change From Baseline (Day 1) in Mean Corpuscular Volume (MCV) Over Period Month 5	0.0 Femtoliters Standard Deviation 1.95	-0.6 Femtoliters Standard Deviation 2.16	-3.0 Femtoliters Standard Deviation 0.00
Change From Baseline (Day 1) in Mean Corpuscular Volume (MCV) Over Period Follow-up	0.2 Femtoliters Standard Deviation 2.10	0.7 Femtoliters Standard Deviation 1.20	-2.8 Femtoliters Standard Deviation 0.96

PRIMARY outcome

Timeframe: Baseline (Day 1) and approximately up to 6 months

Population: Safety population. Only those participants available at the time of assessment were analyzed.

Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Intra-ocular pressure was recorded from Baseline up to Follow-up.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period Month 1	0.2 Millimeters of mercury Standard Deviation 3.47	0.7 Millimeters of mercury Standard Deviation 2.23	1.3 Millimeters of mercury Standard Deviation 2.98
Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period Month 2	0.1 Millimeters of mercury Standard Deviation 3.46	1.2 Millimeters of mercury Standard Deviation 2.83	1.1 Millimeters of mercury Standard Deviation 3.18
Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period Month 3	-1.1 Millimeters of mercury Standard Deviation 4.07	0.7 Millimeters of mercury Standard Deviation 2.64	2.0 Millimeters of mercury Standard Deviation 4.69
Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period Month 4	-0.5 Millimeters of mercury Standard Deviation 2.35	1.2 Millimeters of mercury Standard Deviation 2.71	1.4 Millimeters of mercury Standard Deviation 5.86
Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period Month 5	-1.1 Millimeters of mercury Standard Deviation 3.60	1.2 Millimeters of mercury Standard Deviation 2.59	-0.3 Millimeters of mercury Standard Deviation 5.77
Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period Month Follow-up	-1.3 Millimeters of mercury Standard Deviation 3.13	0.1 Millimeters of mercury Standard Deviation 2.72	0.7 Millimeters of mercury Standard Deviation 3.50

PRIMARY outcome

Timeframe: Approximately up to 6 months (up to follow-up)

Population: Safety population. Only those participants available at the time of assessment were analyzed.

In this dipstick test, the level of blood occult and glucose, ketones, protein in urine samples were recorded as negative, trace, 1+, 2+, and 3+ (the plus sign increases with a higher level of glucose, ketones, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive).

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine blood occult, Month 2, 1+	0 Participants	0 Participants	1 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine blood occult, Month 2, traces	3 Participants	2 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine blood occult, Month 5, traces	0 Participants	2 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine blood occult, Follow-up, traces	1 Participants	0 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine glucose, Month 5, traces	0 Participants	1 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine glucose, Follow-up, 1+ OR 1/4/G/DL (5%)	0 Participants	1 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine ketones, Month 2, traces	1 Participants	0 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine ketones, Follow-up, traces	1 Participants	1 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine protein, Month 2, 1+	0 Participants	0 Participants	1 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine protein, Month 2, traces	3 Participants	0 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine protein, Month 5, 1+	0 Participants	1 Participants	1 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine protein, Follow-up, 1+	0 Participants	1 Participants	0 Participants
Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis Urine protein, Follow-up, traces	3 Participants	2 Participants	1 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population.

Number of participants with ocular and non-ocular AEs and SAEs were separately recorded. An AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. An SAE is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Adverse Events (AEs)and Serious Adverse Events (SAEs) Any SAE, ocular	0 Participants	1 Participants	0 Participants
Number of Participants With Adverse Events (AEs)and Serious Adverse Events (SAEs) Any AE, non-ocular	11 Participants	9 Participants	3 Participants
Number of Participants With Adverse Events (AEs)and Serious Adverse Events (SAEs) Any SAE, non-ocular	2 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events (AEs)and Serious Adverse Events (SAEs) Any AE, ocular	8 Participants	3 Participants	2 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population. Only those participants available at the time of assessment were analyzed.

Visual acuity was measured over 5 months and also during follow-up period. Visual acuity was measured using standardized early treatment of diabetic retinopathy study (ETDRS) visual acuity charts. Visual acuity measurement was performed by an examiner that had been appropriately trained. Screening, Month 2 and Month 5 data were considered as Best Corrected Visual Acuity (BCVA) data. A loss of greater than or equal to 15 letters in BCVA from Baseline was considered of PCI. Data for number of participants who met the criteria for PCI have been presented.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Visual Acuity of Potential Clinical Concern (PCI)	2 Participants	2 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to follow-up (approximately 6 months)

Population: Safety population.

Pupil abnormalities were of different types. Meibomian gland dysfunction was measured as obvious inspissation (debris). Mild injection, no trichiasis (lid thickening), or two step worsening was analyzed. Afferent pupillary defect, motility examination, PERRL, confrontation visual field was measured as a new definite abnormality. Left and right both eyes were examined.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Pupil Examination of PCI	2 Participants	1 Participants	1 Participants

PRIMARY outcome

Timeframe: Up to follow-up (approximately 6 months)

Population: Safety population.

A two step worsening in the conjunctival examination was considered a value of PCI. Participants were analyzed for conjunctival examination up to follow-up (6 months).

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Conjunctival Examination of PCI	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population.

A two step worsening in the anterior chamber examination was considered a value of PCI. The participants were examined for any anterior chamber abnormality. Fibrinous response and obvious aqueous haze were considered abnormalities related to anterior chamber examination.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Anterior Chamber Examination of PCI	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population

A two step change in any of the lens opacity categories was categorized as of PCI. Corneal epithelium was defined as abnormal when punctate keratopathy was measured as mild, moderate, severe; epithelial edema was measured as subtle epithelial haze, mild patchy microcystic changes, diffuse microcystic changes, and/or investigator determined abnormality. Stromal opacity/ edema was measured by investigator when stroma identifies opacity or edema. Corneal staining was measured as obvious (\<=20) localized or diffuse punctate staining areas, severe localized or diffuse punctate staining. Participants were analyzed for any of the mentioned abnormality over 6 weeks (up to follow-up period).

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Corneal Examination of PCI	2 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population

A two step change in any of the lens opacity categories was considered a value of PCI. Aphakia (surgical removal of lens) or pseudophakia was noted if any. Stroma opacity or edema was measured by investigator when it was detected as edema or opacity in stroma.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Lens Opacity of PCI Using Age Related Eye Disease Study (AREDS) Scale	0 Participants	1 Participants	1 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population.

Tear film abnormalities were based on the clinical judgment of investigator. Tear film thickness was analyzed and it was reported whether the film was increased or decreased or was normal. Presence of debris or mucus was also reported. Other test were tear lake analysis and checking of discharge from eyes.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal Tear Films of PCI	3 Participants	1 Participants	1 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population.

Meibomian gland dysfunction was measured as obvious insipisation/debris, mild injection, no trichiasis or lid thickening; inspisation, debris, obvious injection, lid thickening, may have trsichiasis; or a two step worsening. Any 2+ worsening of Meibomian gland function was considered a value of PCI.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Any Grade 2 Plus Worsening of Meibomian Gland Function	1 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: Approximately up to 6 months

Population: Safety population.

Dilation of fundus was examined post dosing up to 6 months. Number of participants with abnormal change from Baseline indicating dilation of fundus of eye was reported. Change from Baseline was the value at indicated time point minus the Baseline value. The abnormalities were posterior vitreous separation, pale optic nerve, fluid in the posterior pole, drusen, thick arterio-venous changes, pigment changes, cystoids, macular edema, drying of posterior fluid or sub-retinal fluid, underlying central atrophy, and retinal pigment epithelial changes etc. Refraction measurement were determined at the screening and 2 month/5 month visits in order to determine BCVA.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Abnormal (Dilated) Fundus Examination	4 Participants	1 Participants	2 Participants

SECONDARY outcome

Timeframe: From Baseline (screening visit), Month 2, and Month 5

Population: Efficacy population included all participants in safety population who have classic choroidal neovascularization present as detected by fluorescein angiography in the previous screening visit.

Change from Baseline in BCVA is the value at indicated time point minus the Baseline value. BCVA at screening visit was used as statistical Baseline. Only data before post-dose intravitreal injection of Avastin/ Lucentis (IVT) has been presented. Arithmetic mean was presented as data values; however statistical analysis is based on means of observed case (OC) data. The screening was used as a Baseline visit that was within or at 14 days of Day 1. Screening visit BCVA values were used to perform statistical comparison at month 2 and 5.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=13 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=12 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=4 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Screening Visit) in BCVA at Month 2 and 5 IVT Treatment naive, Month 2	0.1 Number of letters Standard Deviation 4.85	-5.3 Number of letters Standard Deviation 6.24	-0.7 Number of letters Standard Deviation 3.06
Change From Baseline (Screening Visit) in BCVA at Month 2 and 5 IVT Treatment naive, Month 5	-5.6 Number of letters Standard Deviation 12.60	-5.3 Number of letters Standard Deviation 6.70	-3.0 Number of letters Standard Deviation NA Since only 1 participant was analyzed, SD will not be applicable.
Change From Baseline (Screening Visit) in BCVA at Month 2 and 5 Previously treated with IVT, Month 2	-1.6 Number of letters Standard Deviation 4.28	-3.5 Number of letters Standard Deviation 4.65	—
Change From Baseline (Screening Visit) in BCVA at Month 2 and 5 Previously treated with IVT, Month 5	-1.3 Number of letters Standard Deviation 3.30	-2.0 Number of letters Standard Deviation 7.21	—

SECONDARY outcome

Timeframe: From Baseline (Screening visit) and up to 5 months

Population: Pharmacodynamic subpopulation included participants that were analyzed for PD outcome measures. Only the participants available at the time of assessment were analyzed.

The OCT effect is a pharmacodynamics (PD) measure of daily repeated dosing of Pazopanib. The anatomic effects of pazopanib treatment were limited to investigator determined assessment of OCT central subfield retinal thickness due to heterogeneity of participant population and the low likelihood of utility of central reading center determination. The OCT equipment used was approved by central OTC reading center. OCT scans were collected at indicated time points and were evaluated by Investigator. Thus, grading of further secondary objectives was not performed as per the study team. Change from Baseline is the value at indicated time point minus the Baseline value. The screening was used as a Baseline visit that was within or at 14 days of Day 1. Screening visit BCVA values were used to perform statistical comparison at month 2 and 5.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=13 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=12 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=4 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Treatment naive, Month 4	-19.2 Microns Standard Deviation 52.77	-15.3 Microns Standard Deviation 41.28	-168.5 Microns Standard Deviation 246.78
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Treatment naive, Month 1	8.3 Microns Standard Deviation 48.19	41.1 Microns Standard Deviation 99.51	-18.0 Microns Standard Deviation 37.40
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Treatment naive, Month 2	16.3 Microns Standard Deviation 62.32	18.3 Microns Standard Deviation 45.09	3.0 Microns Standard Deviation 47.32
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Treatment naive, Month 3	-31.3 Microns Standard Deviation 43.43	31.3 Microns Standard Deviation 61.36	12.0 Microns Standard Deviation 5.66
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Treatment naive, Month 5	-15.6 Microns Standard Deviation 52.13	7.3 Microns Standard Deviation 45.11	16.0 Microns Standard Deviation NA No SD can be calculated for one participant analyzed.
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Previously treated, Month 1	46.4 Microns Standard Deviation 130.30	-1.3 Microns Standard Deviation 27.93	36.0 Microns Standard Deviation NA No SD can be calculated for one participant analyzed.
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Previously treated, Month 2	-99.0 Microns Standard Deviation 180.74	-10.0 Microns Standard Deviation 108.19	—
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Previously treated, Month 3	-66.2 Microns Standard Deviation 126.35	2.0 Microns Standard Deviation 37.99	—
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Previously treated, Month 4	-86.8 Microns Standard Deviation 151.02	0.3 Microns Standard Deviation 87.37	—
Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months Previously treated, Month 5	-55.5 Microns Standard Deviation 159.53	3.0 Microns Standard Deviation 66.43	—

SECONDARY outcome

Timeframe: Up to 6 weeks

Population: PD population was planned for analysis of this outcome; however, Data was not collected for this outcome measure.

The analysis was planned to be performed up to 6 months; however, due to heterogeneity of the population and the low likelihood of the utility of the data, the anatomic effects of the pazopanib treatment in this treatment were limited to investigator determined assessment of OCT central subfield retinal thickness. Thus, the study team decided not to have DARC (central reading center) perform the grading for the secondary PD outcomes like lesion size and change with respect to time were not analyzed. Thus, data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 6 months

Population: Safety population.

Number of participants with type of lesion were reported as determined by Investigator. Occult and minimally classic were the two types of lesions reported.

Outcome measures

Outcome measures
Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Number of Participants With Lesion Types Over Period Occult	16 Participants	11 Participants	3 Participants
Number of Participants With Lesion Types Over Period Minimally classic	2 Participants	4 Participants	5 Participants

Adverse Events

5 mg/mL TID

Serious events: 2 serious events

Other events: 15 other events

Deaths: 0 deaths

2 mg/mL TID

Serious events: 1 serious events

Other events: 9 other events

Deaths: 0 deaths

5 mg/mL QD

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	5 mg/mL TID n=19 participants at risk Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months.	2 mg/mL TID n=15 participants at risk Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months.	5 mg/mL QD n=8 participants at risk Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months.
Cardiac disorders Acute coronary syndrome	5.3% 1/19 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data	0.00% 0/15 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data	0.00% 0/8 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data
Injury, poisoning and procedural complications Wrist fracture	5.3% 1/19 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data	0.00% 0/15 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data	0.00% 0/8 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data
Eye disorders Cataract	0.00% 0/19 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data	6.7% 1/15 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data	0.00% 0/8 • AEs and SAEs were collected approximately up to 6 months Safety Population was used to collect AE and SAE data

Other adverse events

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALP, Month 1	-2.8 International units per Liter (IU/L) Standard Deviation 8.01	-0.6 International units per Liter (IU/L) Standard Deviation 11.24	-0.1 International units per Liter (IU/L) Standard Deviation 5.94
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALP, Month 2	1.1 International units per Liter (IU/L) Standard Deviation 7.73	1.8 International units per Liter (IU/L) Standard Deviation 6.03	-2.3 International units per Liter (IU/L) Standard Deviation 8.31
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALP, Month 3	1.2 International units per Liter (IU/L) Standard Deviation 8.19	1.3 International units per Liter (IU/L) Standard Deviation 8.94	-7.5 International units per Liter (IU/L) Standard Deviation 5.92
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALP, Month 4	2.6 International units per Liter (IU/L) Standard Deviation 10.58	-3.5 International units per Liter (IU/L) Standard Deviation 8.64	-1.8 International units per Liter (IU/L) Standard Deviation 6.91
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALP, Month 5	0.7 International units per Liter (IU/L) Standard Deviation 10.82	-1.6 International units per Liter (IU/L) Standard Deviation 8.99	8.3 International units per Liter (IU/L) Standard Deviation 13.80
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALP, Follow-up	3.7 International units per Liter (IU/L) Standard Deviation 13.77	0.1 International units per Liter (IU/L) Standard Deviation 7.98	3.6 International units per Liter (IU/L) Standard Deviation 4.62
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALT, Month 1	2.1 International units per Liter (IU/L) Standard Deviation 3.80	-0.1 International units per Liter (IU/L) Standard Deviation 1.90	-0.4 International units per Liter (IU/L) Standard Deviation 3.93
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALT, Month 2	3.0 International units per Liter (IU/L) Standard Deviation 3.41	2.0 International units per Liter (IU/L) Standard Deviation 4.12	2.1 International units per Liter (IU/L) Standard Deviation 4.94
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALT, Month 3	0.9 International units per Liter (IU/L) Standard Deviation 5.54	-0.7 International units per Liter (IU/L) Standard Deviation 3.39	-0.8 International units per Liter (IU/L) Standard Deviation 3.59
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALT, Month 4	2.1 International units per Liter (IU/L) Standard Deviation 5.07	-1.3 International units per Liter (IU/L) Standard Deviation 4.55	-0.4 International units per Liter (IU/L) Standard Deviation 2.30
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALT, Month 5	2.3 International units per Liter (IU/L) Standard Deviation 3.23	-2.2 International units per Liter (IU/L) Standard Deviation 6.82	-1.0 International units per Liter (IU/L) Standard Deviation 3.00
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period ALT, Follow-up	2.2 International units per Liter (IU/L) Standard Deviation 4.07	-1.1 International units per Liter (IU/L) Standard Deviation 3.21	-0.2 International units per Liter (IU/L) Standard Deviation 2.17
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period AST, Month 1	1.7 International units per Liter (IU/L) Standard Deviation 3.16	0.0 International units per Liter (IU/L) Standard Deviation 3.94	-0.5 International units per Liter (IU/L) Standard Deviation 3.78
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period AST, Month 2	2.4 International units per Liter (IU/L) Standard Deviation 3.42	1.6 International units per Liter (IU/L) Standard Deviation 3.93	1.0 International units per Liter (IU/L) Standard Deviation 2.93
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period AST, Month 3	1.1 International units per Liter (IU/L) Standard Deviation 3.94	-1.0 International units per Liter (IU/L) Standard Deviation 5.56	0.0 International units per Liter (IU/L) Standard Deviation 2.16
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period AST, Month 4	0.1 International units per Liter (IU/L) Standard Deviation 3.18	0.0 International units per Liter (IU/L) Standard Deviation 3.74	1.2 International units per Liter (IU/L) Standard Deviation 2.39
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period AST, Month 5	1.8 International units per Liter (IU/L) Standard Deviation 3.16	-1.4 International units per Liter (IU/L) Standard Deviation 5.33	0.3 International units per Liter (IU/L) Standard Deviation 2.89
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period AST, Follow-up	2.0 International units per Liter (IU/L) Standard Deviation 3.18	-1.1 International units per Liter (IU/L) Standard Deviation 3.78	1.2 International units per Liter (IU/L) Standard Deviation 4.15

Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Bsophils, Follow-up	0.010 Giga per Liter (G/L) Standard Deviation 0.0234	-0.003 Giga per Liter (G/L) Standard Deviation 0.0142	0.00 Giga per Liter (G/L) Standard Deviation 0.00
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Basophils, Month 2	0.008 Giga per Liter (G/L) Standard Deviation 0.0246	0.008 Giga per Liter (G/L) Standard Deviation 0.0157	-0.003 Giga per Liter (G/L) Standard Deviation 0.0271
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Basophils, Month 5	0.007 Giga per Liter (G/L) Standard Deviation 0.0237	0.006 Giga per Liter (G/L) Standard Deviation 0.0168	-0.010 Giga per Liter (G/L) Standard Deviation 0.0141
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Eosinophils, Month 2	-0.043 Giga per Liter (G/L) Standard Deviation 0.1604	0.010 Giga per Liter (G/L) Standard Deviation 0.1204	-0.088 Giga per Liter (G/L) Standard Deviation 0.1784
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Eosinophils, Month 5	0.034 Giga per Liter (G/L) Standard Deviation 0.0952	-0.009 Giga per Liter (G/L) Standard Deviation 0.1324	0.030 Giga per Liter (G/L) Standard Deviation 0.1131
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Eosinophils,Follow-up	0.046 Giga per Liter (G/L) Standard Deviation 0.1623	0.007 Giga per Liter (G/L) Standard Deviation 0.1083	0.032 Giga per Liter (G/L) Standard Deviation 0.0613
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Lymphocytes, Month 2	0.077 Giga per Liter (G/L) Standard Deviation 0.8534	0.051 Giga per Liter (G/L) Standard Deviation 0.4203	-0.031 Giga per Liter (G/L) Standard Deviation 0.3855
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Lymphocytes, Month 5	-0.004 Giga per Liter (G/L) Standard Deviation 0.5848	0.068 Giga per Liter (G/L) Standard Deviation 0.2245	0.130 Giga per Liter (G/L) Standard Deviation 0.3536
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Lymphocytes, Follow-up	-0.058 Giga per Liter (G/L) Standard Deviation 0.4984	0.090 Giga per Liter (G/L) Standard Deviation 0.3412	0.062 Giga per Liter (G/L) Standard Deviation 0.1959
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Monocytes, Month 2	0.025 Giga per Liter (G/L) Standard Deviation 0.1304	0.025 Giga per Liter (G/L) Standard Deviation 0.1621	0.020 Giga per Liter (G/L) Standard Deviation 0.1812
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Monocytes, Month 5	0.006 Giga per Liter (G/L) Standard Deviation 0.2047	0.036 Giga per Liter (G/L) Standard Deviation 0.1272	-0.015 Giga per Liter (G/L) Standard Deviation 0.1202
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Monocytes, Follow-up	-0.035 Giga per Liter (G/L) Standard Deviation 0.1506	0.002 Giga per Liter (G/L) Standard Deviation 0.1293	0.030 Giga per Liter (G/L) Standard Deviation 0.0942
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Platelets, Month 2	-1.1 Giga per Liter (G/L) Standard Deviation 21.84	1.3 Giga per Liter (G/L) Standard Deviation 21.39	11.9 Giga per Liter (G/L) Standard Deviation 29.30
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Platelets, Month 5	1.3 Giga per Liter (G/L) Standard Deviation 33.83	-10.9 Giga per Liter (G/L) Standard Deviation 15.48	70.0 Giga per Liter (G/L) Standard Deviation 62.23
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period Platelets, Follow-up	-3.3 Giga per Liter (G/L) Standard Deviation 22.50	-7.3 Giga per Liter (G/L) Standard Deviation 19.31	8.3 Giga per Liter (G/L) Standard Deviation 7.50
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period White blood cells, Month 2	-0.42 Giga per Liter (G/L) Standard Deviation 1.986	-0.02 Giga per Liter (G/L) Standard Deviation 1.027	0.26 Giga per Liter (G/L) Standard Deviation 1.334
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period White blood cells, Month 5	-1.41 Giga per Liter (G/L) Standard Deviation 2.938	-0.00 Giga per Liter (G/L) Standard Deviation 1.484	0.50 Giga per Liter (G/L) Standard Deviation 1.697
Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period White blood cells, Follow-up	-0.89 Giga per Liter (G/L) Standard Deviation 2.614	0.76 Giga per Liter (G/L) Standard Deviation 2.558	-0.07 Giga per Liter (G/L) Standard Deviation 2.251

Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % monocytes, Month 5	1.24 Percentage of cells Standard Deviation 3.029	0.59 Percentage of cells Standard Deviation 1.358	-0.67 Percentage of cells Standard Deviation 0.611
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % monocytes, Follow-up	0.06 Percentage of cells Standard Deviation 1.803	-0.32 Percentage of cells Standard Deviation 1.236	0.96 Percentage of cells Standard Deviation 3.247
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period %Total neutrophils, Month 2	-2.54 Percentage of cells Standard Deviation 12.125	-0.28 Percentage of cells Standard Deviation 7.709	2.27 Percentage of cells Standard Deviation 3.593
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period %Total neutrophils, Follow-up	-3.16 Percentage of cells Standard Deviation 9.812	0.90 Percentage of cells Standard Deviation 5.801	3.30 Percentage of cells Standard Deviation 24.091
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period %Total neutrophils, Month 5	-6.36 Percentage of cells Standard Deviation 12.291	-1.65 Percentage of cells Standard Deviation 6.020	-2.70 Percentage of cells Standard Deviation 7.826
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % Basophils, Month 2	0.12 Percentage of cells Standard Deviation 0.340	0.12 Percentage of cells Standard Deviation 0.251	-0.05 Percentage of cells Standard Deviation 0.293
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % Basophils, Month 5	0.11 Percentage of cells Standard Deviation 0.274	0.08 Percentage of cells Standard Deviation 0.226	-0.20 Percentage of cells Standard Deviation 0.173
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % Basophils, Follow-up	0.17 Percentage of cells Standard Deviation 0.320	-0.01 Percentage of cells Standard Deviation 0.193	-0.04 Percentage of cells Standard Deviation 0.182
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % Eosinophils, Month 2	-0.44 Percentage of cells Standard Deviation 2.352	0.19 Percentage of cells Standard Deviation 1.366	-1.08 Percentage of cells Standard Deviation 2.089
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % Eosinophils, Month 5	0.60 Percentage of cells Standard Deviation 1.564	0.16 Percentage of cells Standard Deviation 1.879	-0.30 Percentage of cells Standard Deviation 0.964
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % Eosinophils,Follow-up	0.64 Percentage of cells Standard Deviation 2.601	0.04 Percentage of cells Standard Deviation 1.828	-0.56 Percentage of cells Standard Deviation 4.245
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % lymphocytes, Month 2	2.29 Percentage of cells Standard Deviation 11.781	-0.52 Percentage of cells Standard Deviation 7.788	-0.96 Percentage of cells Standard Deviation 4.260
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % lymphocytes, Month 5	4.42 Percentage of cells Standard Deviation 9.734	0.83 Percentage of cells Standard Deviation 4.759	3.87 Percentage of cells Standard Deviation 8.051
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % lymphocytes, Follow-up	2.29 Percentage of cells Standard Deviation 7.790	-0.62 Percentage of cells Standard Deviation 4.021	-3.66 Percentage of cells Standard Deviation 17.637
Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period % monocytes, Month 2	0.57 Percentage of cells Standard Deviation 1.671	0.50 Percentage of cells Standard Deviation 1.974	-0.19 Percentage of cells Standard Deviation 1.277

Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Total bilirubin, Follow-up	-1.1 Micromoles per Liter (umol/L) Standard Deviation 2.43	0.3 Micromoles per Liter (umol/L) Standard Deviation 2.97	-0.8 Micromoles per Liter (umol/L) Standard Deviation 3.35
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Direct bilirubin, Month 1	-0.1 Micromoles per Liter (umol/L) Standard Deviation 0.47	-0.2 Micromoles per Liter (umol/L) Standard Deviation 0.58	0.3 Micromoles per Liter (umol/L) Standard Deviation 0.71
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Direct bilirubin, Month 2	0.2 Micromoles per Liter (umol/L) Standard Deviation 0.92	0.0 Micromoles per Liter (umol/L) Standard Deviation 0.91	0.5 Micromoles per Liter (umol/L) Standard Deviation 0.93
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Direct bilirubin, Month 3	-0.1 Micromoles per Liter (umol/L) Standard Deviation 0.64	-0.5 Micromoles per Liter (umol/L) Standard Deviation 0.90	0.0 Micromoles per Liter (umol/L) Standard Deviation 0.0
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Direct bilirubin, Month 4	-0.1 Micromoles per Liter (umol/L) Standard Deviation 0.51	-0.1 Micromoles per Liter (umol/L) Standard Deviation 0.99	0.8 Micromoles per Liter (umol/L) Standard Deviation 1.10
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Direct bilirubin, Month 5	0.1 Micromoles per Liter (umol/L) Standard Deviation 0.70	-0.1 Micromoles per Liter (umol/L) Standard Deviation 0.70	0.0 Micromoles per Liter (umol/L) Standard Deviation 0.0
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Direct bilirubin, Follow-up	-0.1 Micromoles per Liter (umol/L) Standard Deviation 1.00	-0.2 Micromoles per Liter (umol/L) Standard Deviation 1.17	0.4 Micromoles per Liter (umol/L) Standard Deviation 0.89
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Total bilirubin, Month 1	-0.7 Micromoles per Liter (umol/L) Standard Deviation 3.98	-1.4 Micromoles per Liter (umol/L) Standard Deviation 2.02	0.4 Micromoles per Liter (umol/L) Standard Deviation 2.26
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Total bilirubin, Month 2	0.3 Micromoles per Liter (umol/L) Standard Deviation 1.78	0.2 Micromoles per Liter (umol/L) Standard Deviation 2.70	0.5 Micromoles per Liter (umol/L) Standard Deviation 3.82
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Total bilirubin, Month 3	-1.2 Micromoles per Liter (umol/L) Standard Deviation 4.04	-0.6 Micromoles per Liter (umol/L) Standard Deviation 2.50	-2.0 Micromoles per Liter (umol/L) Standard Deviation 1.63
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Total bilirubin, Month 4	-0.3 Micromoles per Liter (umol/L) Standard Deviation 2.02	-0.9 Micromoles per Liter (umol/L) Standard Deviation 1.52	-0.4 Micromoles per Liter (umol/L) Standard Deviation 2.97
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Total bilirubin, Month 5	-0.7 Micromoles per Liter (umol/L) Standard Deviation 2.28	-0.5 Micromoles per Liter (umol/L) Standard Deviation 2.50	-2.0 Micromoles per Liter (umol/L) Standard Deviation 2.00
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Creatinine, Month 2	3.5 Micromoles per Liter (umol/L) Standard Deviation 9.65	3.0 Micromoles per Liter (umol/L) Standard Deviation 9.23	-5.0 Micromoles per Liter (umol/L) Standard Deviation 7.07
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Creatinine, Month 5	-0.5 Micromoles per Liter (umol/L) Standard Deviation 5.16	2.3 Micromoles per Liter (umol/L) Standard Deviation 5.44	-6.0 Micromoles per Liter (umol/L) Standard Deviation 5.20
Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period Creatinine, Follow-up	4.3 Micromoles per Liter (umol/L) Standard Deviation 8.65	3.5 Micromoles per Liter (umol/L) Standard Deviation 8.66	-7.0 Micromoles per Liter (umol/L) Standard Deviation 14.46

Measure	5 mg/mL TID n=19 Participants Eligible participants received 5 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	2 mg/mL TID n=15 Participants Eligible participants received 2 mg/mL Pazopanib eye drops three times daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.	5 mg/mL QD n=8 Participants Eligible participants received 5 mg/mL Pazopanib eye drops once daily for a treatment period of five months and were followed-up for 7-14 days after the last dose of the study drug.
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Calcium, Month 2	0.000 Millimoles per Liter (mmol/L) Standard Deviation 0.1006	-0.020 Millimoles per Liter (mmol/L) Standard Deviation 0.0840	-0.050 Millimoles per Liter (mmol/L) Standard Deviation 0.1189
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Calcium, Month 5	-0.006 Millimoles per Liter (mmol/L) Standard Deviation 0.1105	-0.045 Millimoles per Liter (mmol/L) Standard Deviation 0.0934	-0.100 Millimoles per Liter (mmol/L) Standard Deviation 0.0917
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Calcium, Follow-up	-0.026 Millimoles per Liter (mmol/L) Standard Deviation 0.0902	-0.010 Millimoles per Liter (mmol/L) Standard Deviation 0.0542	-0.028 Millimoles per Liter (mmol/L) Standard Deviation 0.1221
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Chloride, Month 2	0.1 Millimoles per Liter (mmol/L) Standard Deviation 2.59	-0.2 Millimoles per Liter (mmol/L) Standard Deviation 1.99	0.5 Millimoles per Liter (mmol/L) Standard Deviation 1.77
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Chloride, Month 5	-0.3 Millimoles per Liter (mmol/L) Standard Deviation 2.45	0.5 Millimoles per Liter (mmol/L) Standard Deviation 1.37	-2.0 Millimoles per Liter (mmol/L) Standard Deviation 1.73
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Chloride, Follow-up	0.0 Millimoles per Liter (mmol/L) Standard Deviation 2.42	0.1 Millimoles per Liter (mmol/L) Standard Deviation 1.70	-0.2 Millimoles per Liter (mmol/L) Standard Deviation 2.59
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period CO2, Month 2	-0.4 Millimoles per Liter (mmol/L) Standard Deviation 2.17	-1.3 Millimoles per Liter (mmol/L) Standard Deviation 2.14	-1.3 Millimoles per Liter (mmol/L) Standard Deviation 2.60
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period CO2, Month 5	0.3 Millimoles per Liter (mmol/L) Standard Deviation 2.00	-1.1 Millimoles per Liter (mmol/L) Standard Deviation 2.07	-1.0 Millimoles per Liter (mmol/L) Standard Deviation 5.29
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period CO2, Follow-up	-0.3 Millimoles per Liter (mmol/L) Standard Deviation 2.67	-0.6 Millimoles per Liter (mmol/L) Standard Deviation 1.86	-0.6 Millimoles per Liter (mmol/L) Standard Deviation 3.91
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Glucose, Month 2	-0.26 Millimoles per Liter (mmol/L) Standard Deviation 1.087	0.46 Millimoles per Liter (mmol/L) Standard Deviation 1.947	0.95 Millimoles per Liter (mmol/L) Standard Deviation 1.622
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Glucose, Month 5	-0.85 Millimoles per Liter (mmol/L) Standard Deviation 1.167	-0.03 Millimoles per Liter (mmol/L) Standard Deviation 1.698	1.70 Millimoles per Liter (mmol/L) Standard Deviation 3.329
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Glucose, Follow-up	-0.16 Millimoles per Liter (mmol/L) Standard Deviation 1.315	0.22 Millimoles per Liter (mmol/L) Standard Deviation 2.561	0.34 Millimoles per Liter (mmol/L) Standard Deviation 1.354
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Potassium, Month 2	-0.01 Millimoles per Liter (mmol/L) Standard Deviation 0.341	-0.02 Millimoles per Liter (mmol/L) Standard Deviation 0.251	-0.20 Millimoles per Liter (mmol/L) Standard Deviation 0.385
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Potassium, Month 5	0.02 Millimoles per Liter (mmol/L) Standard Deviation 0.544	-0.11 Millimoles per Liter (mmol/L) Standard Deviation 0.406	-0.53 Millimoles per Liter (mmol/L) Standard Deviation 0.404
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Potassium, Follow-up	-0.06 Millimoles per Liter (mmol/L) Standard Deviation 0.410	-0.06 Millimoles per Liter (mmol/L) Standard Deviation 0.277	-0.44 Millimoles per Liter (mmol/L) Standard Deviation 0.114
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Sodium, Month 2	0.0 Millimoles per Liter (mmol/L) Standard Deviation 1.81	-1.0 Millimoles per Liter (mmol/L) Standard Deviation 1.87	0.3 Millimoles per Liter (mmol/L) Standard Deviation 2.25
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Sodium, Month 5	-0.6 Millimoles per Liter (mmol/L) Standard Deviation 2.58	-1.1 Millimoles per Liter (mmol/L) Standard Deviation 0.94	-2.7 Millimoles per Liter (mmol/L) Standard Deviation 1.53
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Sodium, Follow-up	-1.1 Millimoles per Liter (mmol/L) Standard Deviation 2.77	-1.2 Millimoles per Liter (mmol/L) Standard Deviation 2.23	-0.6 Millimoles per Liter (mmol/L) Standard Deviation 0.55
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Urea/BUN, Month 2	-0.09 Millimoles per Liter (mmol/L) Standard Deviation 1.417	0.12 Millimoles per Liter (mmol/L) Standard Deviation 1.267	0.06 Millimoles per Liter (mmol/L) Standard Deviation 1.130
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Urea/BUN, Month 5	0.11 Millimoles per Liter (mmol/L) Standard Deviation 0.905	0.67 Millimoles per Liter (mmol/L) Standard Deviation 1.034	-0.17 Millimoles per Liter (mmol/L) Standard Deviation 0.764
Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period Urea/BUN, Follow-up	-0.36 Millimoles per Liter (mmol/L) Standard Deviation 1.509	0.40 Millimoles per Liter (mmol/L) Standard Deviation 1.059	1.00 Millimoles per Liter (mmol/L) Standard Deviation 0.500